Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Revises Study Protocol Review To Prevent Another Trasylol Fiasco

This article was originally published in The Pink Sheet Daily

Executive Summary

Protocol Review Committee purview extended beyond prospective clinical trials based upon independent review findings.

You may also be interested in...



Trasylol Could Face Labeling Changes After Joint Advisory Panel

Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.

Trasylol Could Face Labeling Changes After Joint Advisory Panel

Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.

Bayer Suspends Senior Staffers For Failure To Disclose Trasylol Data To FDA

The company will publish findings of independent investigation, which could recommend corrective action plan.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel